To date, more than a dozen monoclonal antibodies (mAbs) targeting PD-1 or PD-L1 (nivolumab, pembrolizumab, atezolizumab, etc.)have been approved for cancer treatment, and many mAbs are also in clinical trials [10,11,12,13,14,15]. The gene discussed is CD274; the disease is cancer.